GHRP-6 Plus GHRH Emerges as Potent, Safe Diagnostic Alternative to Insulin Tolerance Test
Background
Growth hormone deficiency (GHD) is diagnosed and treated through protocols that carry meaningful risk or inconvenience. The standard provocative test — the insulin tolerance test (ITT) — induces hypoglycemia and is contraindicated in many patients, creating a clinical gap for safer alternatives. Growth hormone secretagogues (GHS), including peptidergic compounds such as GHRP-6 and non-peptidergic agents like MK-677, act at the GHS receptor (GHSR) to potently stimulate GH release. Understanding the endogenous ligand of GHSR remains an open question with profound implications for the hypothalamic control of GH secretion in humans.
Study Design
A narrative clinical review evaluated the therapeutic and diagnostic potential of GHS compounds, including GHRP-6 and MK-677, across three proposed clinical domains: treatment of GHD states, diagnosis of GHD, and non-endocrinological (particularly cardiovascular) applications. The review assessed combined administration of GHRH plus GHRP-6, both at saturating doses, as a provocative GH stimulation protocol. Comparative analysis of GHS versus exogenous GH therapy and versus the ITT was conducted. No single controlled trial was the primary source; the paper synthesizes the existing evidence base to outline the clinical future of the drug class.
Results
GHS compounds are described as potent releasers of GH in man, though they carry lower potency compared to exogenous GH therapy. Their profile of GH secretion is characterized as more physiological and safer than exogenous GH administration, suggesting suitability for indications where medium GH doses have demonstrated efficacy. The cardiovascular actions of GHS are described as highly promising, though specific quantitative data are not provided in the abstract.
The combined administration of GHRH plus GHRP-6, both at saturating doses, is currently the most powerful releaser of GH in humans — described as devoid of side effects and convenient for patients, positioning it as a viable alternative to the insulin tolerance test for diagnosing GHD in adults.
The review further notes that once the endogenous ligand of the GHS receptor is identified, understanding of hypothalamic GH control will fundamentally shift, likely altering both diagnostic and therapeutic practices that are currently standard.
Key Findings
- GHRH + GHRP-6 at saturating doses is the most powerful GH-releasing combination known in humans.
- GHS have lower potency than exogenous GH but offer a more physiological and safer secretion profile.
- Combined GHRH + GHRP-6 proposed as an alternative to the insulin tolerance test for diagnosing adult GHD.
- Cardiovascular actions of GHS described as highly promising, though not yet quantified.
- Identification of the endogenous GHS receptor ligand expected to fundamentally reshape GH diagnostics and therapy.
Why It Matters
Clinicians and researchers evaluating GH axis function may have a meaningful alternative to the hypoglycemia-inducing ITT already in view: the GHRH + GHRP-6 combination at saturating doses is flagged as the most potent and side-effect-free provocative GH stimulus currently known. For practitioners using or studying GHS compounds, this framing reinforces that peptidergic GHS are not merely performance-adjacent compounds — they have a formal diagnostic role. The cardiovascular signal deserves attention: the abstract explicitly highlights cardiovascular effects as highly promising, suggesting future protocols may extend far beyond the GH axis. The identification of the endogenous GHSR ligand (subsequently identified as ghrelin) is flagged as the pivotal unknown that will reshape the entire field — underscoring that the mechanistic story for these compounds was, at the time of publication, still incomplete.
